Revolution Medicines Rallies After Phase 3 Pancreatic Cancer Trial Doubles Survival Versus Chemo

Revolution Medicines stock rises after Phase 3 daraxonrasib data show survival gains in pancreatic cancer, with regulatory filings planned.

Merk And Daiichi Sankyo JV Receives FDA Priority Review For Ifinatamab Deruxtecan For The Treatment Of Adult Patients With Extensive-Stage Small Cell Lung Cancer

Ifinatamab deruxtecan is a specifically engineered, potential first-in-class B7-H3 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed by Daiichi Sankyo and Merck.

Sun Pharma Nears Final Offer For Organon In Largest Overseas Bet

Sun Pharma prepares $12 billion Organon bid after due diligence, advancing financing for its biggest global acquisition push.

Summit Therapeutics Has Scarcity Value In A Crowded Drug Race: Analyst

Stifel initiates coverage on Summit Therapeutics (SMMT) with a Buy rating and $45 price target, citing ivonescimab's $200B market potential.

Merck Lowered Terns Pharmaceuticals Offer Price After Trial Data Review

Merck cuts Terns deal price after TERN-701 data review, while maintaining interest amid competition and CML treatment comparisons.

What's Going On With Merck Stock Tuesday?

Merck begins tender offer for Terns at $53 per share as part of its planned acquisition announced in March 2026.

Merck Commences Cash Tender Offer to Acquire All Outstanding Shares of Terns Pharmaceuticals for $53.00 Per Share

Evaxion Announces Final Patient Visit In One-Year Extension Phase 2 Trial Of Personalized Melanoma Cancer Vaccine EVX-01

EVX-01 is a personalized cancer vaccine currently being evaluated as a treatment for advanced melanoma (skin cancer). In the first two years of the phase 2 trial, patients were treated with EVX-01 in combination with

JP Morgan Maintains Overweight on Merck & Co, Raises Price Target to $135

JP Morgan analyst Chris Schott maintains Merck & Co (NYSE:MRK) with a Overweight and raises the price target from $125 to $135.

Merck Says EU Approves KEYTRUDA, In Combination With Paclitaxel, With Or Without Bevacizumab, For Treatment Of Platinum-Resistant Epithelial Ovarian, Fallopian Tube Or Primary Peritoneal Carc

The KEYTRUDA regimen is the first and only PD-1 inhibitor-based treatment approved in the European Union for these patientsApproval supported by data from the Phase 3 KEYNOTE-B96 trial in which the KEYTRUDA regimen